Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,433.74
(
-0.90%
)
US TECH 100
28,468.20
(
-1.12%
)
Dow Jones
49,650.12
(
-0.83%
)
Brent Oil
106.45
(
2.17%
)
Bitcoin
79,342.47
(
-2.11%
)
News Focus
News Focus
Post# of 257575
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122986
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 151628

Friday, 11/02/2012 12:37:54 PM

Friday, November 02, 2012 12:37:54 PM

Post# of 257575

Copaxone is still holding more than 40% of MS drugs market share.

What’s impressive is that Copaxone’s US share of patient Rx’s for MS has not changed to a significant degree from the launch of Gilenya or the uptake in Tysabri from JC-testing. Rather, Copaxone’s US share has remained at or near 40% for the past few years.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today